Skip to Main Content
For healthcare professionals

DAREON®-Lung-1: Phase III trial of first-line obrixtamig plus SoC in patients with ES-SCLC (NCT07472517)

 

DAREON® -Lung-1: A Phase III, multi-center, open-label, randomized trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer1

DAREON®-Lung-1 (NCT07472517, 1438-0012)
DAREON®-Lung-1 (NCT07472517, 1438-0012)

DLL3, delta-like ligand 3; ECOG PS, Eastern Cooperative Oncology Group performance status; ES-SCLC, extensive-stage small cell lung cancer; OR, overall response; PFS, progression-free survival; PRO, patient reported outcome; SoC, standard of care

References

  1. ClinicalTrials.gov. NCT07472517. https://clinicaltrials.gov/study/NCT07472517 (Accessed: April 2026).